Infinium Pharmachem Ltd. · NSE:INFINIUM
Infinium Pharmachem — Investor Presentation (February 2024)
34 slides from Infinium Pharmachem's investor presentation, Feb 29, 2024
Slide 1: Exchange filing cover letter for investor meeting presentation
29th February, 2024 T o, The Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, G Block Bandra Kurla Complex, Mumbai – 400 051 NSE Symbol: INFINIUM Sub:: - Presentation for Analysts/Institutional Investors Meeting Dear Sir / Madam, ursuantto
Slide 2: Infinium PharmaChem Limited Corporate Presentation February 2024
INFINIUM PHARMACHEM LIMITED CORPORATE PRESENTATION FEBRUARY 2024 1
Slide 3: Safe Harbour
Safe Harbour The presentation has been prepared by Infinium PharmaChem Limited (the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form th
Slide 4: Infinium at a Glance
Infinium at a Glance Incorporated in 2003 at Anand, Gujarat. Manufacturing high-quality Iodine Derivatives & APIs. Catering majorly to pharmaceutical Industry. Works on CRAMS model. 4-years Revenue CAGR of 43.27%. EBITDA margin expanded 2x in last 4-years. Consistent Gross margin of 22-29% over last
Slide 5: Consistently Creating Milestones Over Time
Consistently Creating Milestones Over Time 2019: Expanded to 2021: Crossed Rs. 50 2021: Augmentation of 2022: Focused on 2023: Listed on 15+ countries. crores revenue. production capacity. backward integration. NSE. 114 99 71 39 FY 20 FY 21 FY 22 FY 23 Consolidated Revenue (in INR Crore) 4
Slide 6: Manufacturing Tough Chemistry
Manufacturing Tough Chemistry • Iodine is a nonmetallic element and cannot be produced using chemical synthesis, from an industry standpoint it can be only extracted as iodine containing resources. • The global iodine market share is divided by source, form, application and region: Based on source B
Slide 7: Our capabilities
Our capabilities 1 Manufacturing and supplying value-added APIs and Iodine Derivatives since 2003. 2 Robust capacity of 1800 MT ensuring consistent and reliable production. Steady performance with notable scalability potential with annual production 3 output of 360MT. Compliant with quality & regula
Slide 8: Marquee Clientele
Marquee Clientele Industries served Companies served Pharmaceuticals Chemical Cosmetics Bio-Tech Nutraceutical Electronics Solar Paints/ Coatings Animal Feed Textiles 7
Slide 9: Creating Products, Improving Health
Creating Products, Improving Health Key Iodine derivatives Featured API • Dess Martin Periodine • Potassium Iodide (IP, BP,USP,JP,EP,ACS)- Used for • Iodobenzene treating hyperthyroidism. • N- Iodosuceinamide • Pralidoxime Iodide- Antidote and cholinesterase • Lithium Iodide Hydrate • Tetrabutyl-amm
Slide 10: Group Companies
Group Companies Infinium Group Infinium PharmaChem Infinium Healthcare Private Limited Limited Infinium Green Energy Private Limited Shanghai Tajilin Industrial Co. Limited No Holding of Infinium PharmaChem Limited. Only Common directors. Infinium PharmaChem Limited holds 51% Infinium PharmaChem Lim
Slide 11: Infinium Healthcare Private Limited
Infinium Healthcare Private Limited Infinium Healthcare Private Limited has land available at Dahej, Gujarat for expanding operations in healthcare sector and is proposing an API plant at Dahej. Iodine is a precious element on earth and is rarely available. Extracting it is difficult depending upon
Slide 12: Iodine Extraction- Our approach to the problem
Iodine Extraction- Our approach to the problem What does IBL Elements do: USP of the Project • Extracts iodine from saltwater collected during oil and gas • Own land of 42 acres in Oklahoma, USA (purchased under extraction. distress sale from First National Bank). Present value ~ • Patented process
Slide 13: Shanghai Tajilin Industrial Co. Limited
Shanghai Tajilin Industrial Co. Limited % of holding Established in March 2019, Shanghai Tajilin Industrial Co.,Ltd is a Joint venture agreement entered between Infinum Pharmachem Limited and Shanghai Witofly Chemical Co. Ltd. Incorporated in China for exclusive distributorship in China Market for I
Slide 14: Infinium Green Energy Private Limited
Infinium Green Energy Private Limited Located in Dhutapur (Ramnagar), Jamnagar Gujarat. Infinium Green Energy Private Limited is Bio coal manufacturer that deals in Bio Coal, Bio Gas, Bio Energy, agro waste briquettes, white coal and Biomass Briquettes and other products related to renewable energy
Slide 15: Fast Growth Trajectory
Fast Growth Trajectory Consolidated (In INR Crore) 114 17 99 71 11 10 39 7 6 3 3 1 FY 20 FY 21 FY 22 FY 23 Revenue EBITDA PAT *Note: Revenue is core revenue from operations. EBITDA is Revenue from operations reduced by all expenses except finance cost, depreciation and amortization and tax expenses
Slide 16: Creating A Superior Shareholder Value
Creating A Superior Shareholder Value 48% 29% 47% 41% 38% 22% 22% 23% 38% 38% 15% 11% 25% 8% 8% 8% 7% 20% 4% 2% FY 2020 FY 2021 FY 2022 FY 2023 FY 20 FY 21 FY 22 FY 23 EBITDA Margin PAT Margin GP Margin ROE ROCE *Note: EBITDA is Revenue from operations reduced by all expenses except finance cost, de
Slide 17: Investment Thesis
Investment Thesis Beyond geographies Backward Integration Expertise in R&D o Expanding reach to over 20+ o Well established relations with o Product portfolio of 200+ Iodine countries globally material suppliers Derivatives o significantly increasing customer base o Navigate many supply chain o Manu
Slide 18: Business Model
Business Model The Company is dealing specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs). The Company undertakes Contract Research and Manufacturing Services (CRAMS) to provide customized and fully confident
Slide 19: Industry Insights- Global Outlook
Industry Insights- Global Outlook Global Iodine Market Global Pharmaceutical Market Global API Market Expected CAGR: 4.95% (2022-30) Expected CAGR: 12.5% (2020-27) Expected CAGR: 6.52% (2022-27) Global Iodine Market (In $ Mn) Global Pharmaceutical Industry (In $ Bn) Global API market (In $ Bn) 970.5
Slide 20: Industry Insights- India Outlook
Industry Insights- India Outlook Indian Pharmaceutical Industry Indian API Market Expected CAGR: 15% (2024-32) Expected CAGR: 8.3% (2021-28) Indian Pharmaceutical Industry (In $ Bn) Indian API market (In $ Bn) 163.1 34.97 19.99 54.6 2024 2032 2021 2028 Source: https://www.imarcgroup.com/india-pharma
Slide 21: Stable Market Scope Across Asia
Stable Market Scope Across Asia Standalone Revenue (In INR Crore) FY 20 FY 21 FY 22 FY 23 0.47 1.57 3.77 11.62 10.46 12.06 8.09 3.16 19.50 20.63 11.69 0.0209 47.55 69.77 3.34 42.24 India China Japan Others India China Japan Others India China Japan Others India China Japan Others • Company has stron
Slide 22: Raw Material Supplies
Raw Material Supplies Procurement distribution (Standalone) FY 20 FY 21 FY 22 FY 23 13.17% 14.03% 27.55% 27.97% 24.54% 6.67% 38.19% 10.92% 47.60% 56.89% 6.74% 11.64% 23.27% 27.45% 37.74% 25.63% India USA China Other India USA China Other India USA China Other India USA China Other Raw materials used
Slide 23: Quality & Regulatory Compliances
Quality & Regulatory Compliances ISO 22000:2005 focus Ranging from early- on Food Safety stage development to WHO- GMP Compliant document control and Management systems Manufacturing Plant pilot scale validation ISO 14001:2015 focus & Production. to bulk scale on environmental ISO 9001-2015 Certifie
Slide 24: Capex for Expansion
Capex for Expansion Expansion plans: • Expansion of current facilities • Extending facilities for Contrast Media that will be used in PET scan. Particulars Planned Incurred Date of completion Expansion 21.92 Crores 15 Crores 31 Mar 2024 Project of current facilities Expansion 11 Crores Nil 31 Dec 20
Slide 25: Strategic Positioning & Growth Outlook
Strategic Positioning & Growth Outlook • Established Iodine manufacturer • Moving up the Value chain • Niche Expertise in landing tough Chemicals. • Launching new product in FY 2025- Expected to contribute approx. 25% growth in topline. • 5 EU-REACH Registration received- Expected to contribute appr
Slide 26: Financial Overview
FINANCIAL OVERVIEW 25
Slide 27: Consolidated Profit & Loss Statement Summary
Consolidated Profit & Loss Statement Summary (In INR Crore) Particulars FY 20 FY 21 FY 22 FY 23 H1FY24 Revenue from Operations 38.84 70.53 99.12 114.22 61.48 Other Income 0.57 0.62 0.93 1.35 0.34 Cost of Goods Sold 30.14 54.86 76.74 80.57 44.71 Gross Profit 8.70 15.67 22.38 33.65 16.77 Gross Profit
Slide 28: Consolidated Balance Sheet Summary
Consolidated Balance Sheet Summary (In INR Crore) Equity and Liabilities FY 20 FY 21 FY 22 FY 23 H1FY24 Assets FY 20 FY 21 FY 22 FY 23 H1 FY24 Equity Share Capital 1.02 1.02 1.02 5.08 13.92 Non- Current Assets Other Equity 3.23 6.01 12.09 17.48 40.01 Property, plant and 4.15 4.72 4.20 18.81 18.94 No
Slide 29: Consolidated Cash Flow Statement Summary
Consolidated Cash Flow Statement Summary (In INR Crore) Particulars FY 20 FY 21 FY 22 FY 23 H1FY24 Cash from Operations 3.03 7.29 11.79 8.55 (15.73) Cash from Investing (1.05) (4.99) (6.63) (4.95) (1.67) Cash from Financing (1.24) (1.16) (1.70) (3.10) 24.19 Net (Decrease)/Increase in cash 0.74 1.13
Slide 30: Annexure
ANNEXURE 29
Slide 31: Vision And Mission
Vision And Mission Vision To be a globally integrated & admired Pharmaceutical & Healthcare company Mission To research, develop & successfully market extremely customized Pharmaceuticals & Healthcare products & services while strictly adopting the highest level of: Effectiveness & Efficiencies
Slide 32: Board Of Directors
Board Of Directors SANJAYKUMAR VITHTHALBHAI PATEL PRAVIN BADHABHAI MADHANI MITESH LAVJIBHAI CHIKHALIYA Promoter and Managing director Promoter and Director Promoter and Director He holds a master degree from Gujarat He is a postgraduate and hold LLB He holds a master degree from Savitribai Universit
Slide 33: Board Of Directors
Board Of Directors KEYUR JAGDISHCHANDRA SHAH TARUN RATILAL DOBARIYA VAISHAKHI AMBRISHBHAI SHUKLA Independent Director Independent Director Independent Director He is a Company Secretary, MBA in With technical know-how in Non- She holds master degree and Graduate Finance and a practicing Insolvency F
Slide 34: Infinium Pharmachem Limited contact details
Infinium Pharmachem Limited Suite #205, "SIGMA PRIME", Second Floor, Nr. Sardar Patel Statue, V.U. Nagar GIDC Road, Vallabh Vidyanagar – 388120, Gujarat, INDIA Phone: +91-2692-238849 / 238850 Email: info@infiniumpharmachem.com Website: https://infiniumpharmachem.com/ Investor Relations Go India Advi
Infinium Pharmachem — Investor Presentation (February 2024) on 6ix